Using idebenone to prevent epilepsy after a stroke

Clinical Multi-center Study of Mitochondrial Brain Protective Agent Idebenone in the Prevention of Post-stroke Epilepsy

This study is testing if a medication called idebenone can help prevent epilepsy in people who have had a stroke.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2700 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Xiangya Hospital of Central South University (Academic / other)
• Locations: 1 site (Changsha, Hunan)
• Trial ID: NCT05987397 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effectiveness of idebenone, a mitochondrial protective agent, in preventing post-stroke epilepsy. Patients who have experienced a stroke will be randomly assigned to receive idebenone for either a short-term period of 14 days or a long-term period of 3 months, while a control group will not receive the intervention. The study aims to assess whether idebenone can reduce the incidence of epilepsy following a stroke. Participants will be monitored for their response to the treatment and any potential side effects.

Who should consider this trial

Good fit: Ideal candidates are patients who have been admitted to the hospital within 24 hours of stroke symptoms and diagnosed with a stroke.

Not a fit: Patients with a history of epilepsy prior to the stroke or serious comorbidities that may lead to seizures will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of developing epilepsy in stroke survivors.

How similar studies have performed: While the use of idebenone is being explored in this context, similar studies have not been widely reported, making this approach relatively novel.

Eligibility criteria

Inclusion Criteria:

* Patients admitted to hospital within 24 hours of stroke symptoms and diagnosed with stroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, intracranial venous sinus thrombosis, etc.) after relevant examinations;
* Able to cooperate with the inspection;
* Sign the informed consent form.

Exclusion Criteria:

* History of epilepsy before stroke;
* A history of serious comorbidities that may lead to seizures (including malignant tumors, specific autoimmune diseases, severe electrolyte abnormalities, end-stage renal disease, and severe head trauma);
* Secondary stroke caused by head trauma or surgery;
* Other patients that the researchers think need to be excluded.

Where this trial is running

Changsha, Hunan

• Xiangya Hospital, Central South University — Changsha, Hunan, China (Recruiting)

Study contacts

• Study coordinator: Li Feng, PhD

Conditions Post Stroke Epilepsy; post-stroke epilepsy; idebenone